BioCryst to Report First Quarter 2023 Financial Results on May 3
BioCryst Pharmaceuticals (BCRX) announced it will report its first quarter 2023 financial results on May 3, 2023.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCryst Pharmaceuticals (BCRX) announced it will report its first quarter 2023 financial results on May 3, 2023. The management will host a conference call and webcast at 8:30 a.m. ET to discuss these results and provide a corporate update. Interested parties can access the live call by dialing the designated numbers or via the company's investor website. BioCryst focuses on developing novel oral medicines for rare diseases, with its product ORLADEYO (berotralstat) approved in the U.S. and several international markets. In addition, the company is advancing programs targeting the complement system, including the clinical development of BCX10013. More details are available on their website.
Details
News Market Reaction – BCRX
The recorded move for BCRX in the trading session of this news was -0.13%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., April 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2023 financial results on Wednesday, May 3, 2023.
BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 1-866-777-2509 for domestic callers and 1-412-317-5413 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.
BCRXW
Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.